Evidence map›Paper›PMID 40777831›Full record

ArticleFrontiers in veterinary science2025

Causal inference study of PRRSV-MLV vaccine dosing effects on wean-to-finish performance during outbreaks.

Swaminathan Jayaraman, Tyler Bauman, Amy Maschhoff, Caleb Shull, Peng Li, Edison Magalhaes, Giovani Trevisan, Daniel C L Linhares, Chunlin Li, Gustavo S Silva

Abstract read
In one paragraph

Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Swaminathan JayaramanDepartment of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.
Tyler BaumanThe Maschhoffs Ltd., Carlyle, IL, United States.
Amy MaschhoffThe Maschhoffs Ltd., Carlyle, IL, United States.
Caleb ShullThe Maschhoffs Ltd., Carlyle, IL, United States.
Peng LiDepartment of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.
Edison MagalhaesDepartment of Animal Science, College of Agriculture and Life Sciences, Iowa State University, Ames, IA, United States.
Giovani TrevisanDepartment of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.
Daniel C L LinharesDepartment of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.
Chunlin LiDepartment of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA, United States.
Gustavo S SilvaDepartment of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) greatly impacts swine production, and vaccination is the main method for reducing its economic effects on grow-finish populations. To cut costs, some producers use half-doses of modified live virus (MLV) vaccines, but the effectiveness of this approach during disease outbreaks is not well understood. This retrospective observational study used causal inference techniques to assess the impact of full-dose versus half-dose PRRSV-MLV vaccination on mortality and other key production outcomes in growing pigs experiencing PRRSV-2 outbreaks. Data analysis included 158 pig groups (47 nurseries, 111 finishing) from the Midwest United States that experienced PCR-confirmed PRRSV-2 outbreaks between 2021 and 2022, predominantly with L1C and L1A lineages. Mortality was established as the primary outcome, with cull rates, average daily gain, veterinary medicine costs, and percentage of grade A pigs at market as secondary outcomes. Using targeted maximum likelihood estimation (TMLE), a doubly robust causal inference technique, the study estimated the causal effects of vaccination dosage while accounting for potential confounders, including season, year, vaccine type, timing of vaccination, nursery stocking density, and presence of concurrent diseases. The analysis revealed distinct phase-specific effects: in the nursery, full-dose vaccination was associated with higher mortality difference (8.84, 95% CI: 4.7, 12.98) and increased veterinary costs (1.52 dollars/pig, 95% CI: 1.13, 1.91). However, in the finishing phase, full-dose vaccination significantly reduced the mortality difference (-3.40, 95% CI: -4.66, -2.29) despite slightly higher veterinary costs (0.47 dollars/pig, 95% CI: 0.03, 0.9). No significant differences between dosing strategies were observed in average daily gain, cull rates, or percentage of grade A pigs at the market. These findings suggest that while nursery groups vaccinated with full-dose had higher mortality and costs, it provided protective benefits during the economically critical finishing phase. For swine producers and veterinarians, these results indicate that the economic advantage of half-dose vaccination strategies should be carefully weighed against the increased mortality, particularly in systems with recurring PRRSV challenges. This study demonstrates the value of causal inference methods in analyzing real-world vaccination outcomes and provides evidence-based guidance for optimizing PRRSV vaccination protocols in commercial swine production.

Indexed as

causal inferencemodified live virus vaccinesporcine reproductive and respiratory syndrome virusswine productionTMLEvaccine efficacy

Identifiers

PMID40777831
PMCPMC12330286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.